The introduction of atypical antipsychotics represents an advance in the treatment of schizophrenia because they are generally better tolerated than conventional antipsychotics and have been ...

New safety study links sedative use to increased stroke risk. A large UK study involving more than 165,000 people with dementia has found that the drug risperidone increases the risk of stroke in all ...

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...

Please provide your email address to receive an email when new articles are posted on . An oral, ultra-long-acting, extended-release risperidone capsule provided sustained therapeutic levels of ...

The antipsychotic cariprazine (Reagila) is not only more effective than risperidone in treating patients with schizophrenia and persistent negative symptoms (PNS), it is also safe and effective for ...

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...

A large UK study of over 165,000 dementia patients finds risperidone raises stroke risk in all users, prompting concerns over ...

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS, February 25, 2025--(BUSINESS WIRE)--Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), ...

Background: To compare the efficacy and tolerability of paliperidone extended-release (ER) with risperidone immediate-release using propensity score methodology. Methods: Six double-blind, randomized, ...

Study finds risperidone did not improve PTSD symptoms. — August 2, 2011 -- Risperidone, antipsychotic medication normally prescribed to treat symptoms of schizophrenia and bipolar disorder, may ...

This study examines the plan characteristics associated with generic risperidone use and spending and adherence outcomes associated with use among Medicare Advantage Part D beneficiaries. Objectives: ...

UZEDY (risperidone) extended-release injectable suspension, for subcutaneous use, is indicated for the treatment of schizophrenia in adults. In clinical trials, UZEDY significantly reduced the risk of ...